GlobeNewswire Inc.··NaOpus Genetics Secures $155M Non-Dilutive Funding to Accelerate Retinal Gene Therapy Pipeline
Opus Genetics secures $155M non-dilutive funding from Oberland Capital, extending cash runway through 2029 and accelerating gene therapy development for inherited retinal diseases.
IRDclinical developmentgene therapy